Term ends no later than Sep 22, 2029 · Medium confidence
20-year base term ends Aug 29, 2028
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Aug 29, 2008
Sep 22, 2029
Mar 26, 2013
This patent's term runs 389 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 29, 2008, when this application, 12/200,939, was filed | Aug 29, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +389 days, USPTO patent term adjustment record | Sep 22, 2029 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Sep 22, 2029 | Medium confidence |
This family
| US 8,404,846 | this patent no later than Sep 2029 | no later than Sep 2029 |
| US 8,389,541 | In force Aug 2028 | Aug 2028 |
| US 8,846,927 | In force Aug 2028 | Aug 2028 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 3, 2008 Reel 21799, frame 925 | Claridge, Stephen; Isakovic, Ljubomir; Mannion, Michael; Raeppel, Stephane; Saavedra, Oscar Mario; Gaudette, Frederic; Zhan, Lijie; Zhou, Nancy Z.; Raeppel, Franck; Deziel, Robert; Vaisburg, Arkadii; Uno, Tetsuyuki | Methylgene Inc. | Assignment of Assignor's Interest |
| Oct 19, 2010 Reel 25159, frame 476 | 922209129 Quebec Inc., (Formerly "Methylgene, Inc.") | 7503547 Canada, Inc. | Change of Name |
| Oct 27, 2010 Reel 25200, frame 827 | Methylgene, Inc. | 92229129 Quebec Inc. | Change of Name |
| Oct 27, 2010 Reel 25201, frame 647 | 7503547 Canada Inc. | Methylgene, Inc. | Merger |
| Oct 19, 2022 Reel 61470, frame 462 | Methylgene Inc. | Methylgene ULC | Change of Name |
| Oct 19, 2022 Reel 61470, frame 650 | Methylgene ULC | Mirati Therapeutics, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Sep 22, 2029. We will not guess the cap.